Leylah Drusbosky

2.5k total citations
72 papers, 522 citations indexed

About

Leylah Drusbosky is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Leylah Drusbosky has authored 72 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Cancer Research, 39 papers in Pulmonary and Respiratory Medicine and 25 papers in Oncology. Recurrent topics in Leylah Drusbosky's work include Cancer Genomics and Diagnostics (44 papers), Lung Cancer Treatments and Mutations (22 papers) and Acute Myeloid Leukemia Research (16 papers). Leylah Drusbosky is often cited by papers focused on Cancer Genomics and Diagnostics (44 papers), Lung Cancer Treatments and Mutations (22 papers) and Acute Myeloid Leukemia Research (16 papers). Leylah Drusbosky collaborates with scholars based in United States, Canada and Spain. Leylah Drusbosky's co-authors include Estelamari Rodríguez, Chukwuemeka Ikpeazu, Christopher R. Cogle, Elizabeth Wise, Kabir Mody, Amy Meacham, Pashtoon Murtaza Kasi, Mehmet Asım Bilen, Jason S. Starr and Edward W. Scott and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Leylah Drusbosky

62 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leylah Drusbosky United States 13 223 198 188 183 105 72 522
Srinivas K. Tantravahi United States 11 173 0.8× 245 1.2× 125 0.7× 242 1.3× 199 1.9× 70 597
Smitha Menon United States 11 300 1.3× 134 0.7× 73 0.4× 128 0.7× 50 0.5× 18 474
M.C. Cox United States 10 180 0.8× 91 0.5× 74 0.4× 177 1.0× 50 0.5× 23 429
Jean Lopategui United States 13 209 0.9× 129 0.7× 148 0.8× 121 0.7× 35 0.3× 27 521
Florian Huemer Austria 13 323 1.4× 114 0.6× 76 0.4× 133 0.7× 25 0.2× 46 502
Marco Bono Italy 14 185 0.8× 189 1.0× 133 0.7× 125 0.7× 23 0.2× 33 446
Stephen J Chanock United States 6 159 0.7× 153 0.8× 100 0.5× 44 0.2× 125 1.2× 7 434
Honghui Huang China 14 123 0.6× 183 0.9× 137 0.7× 43 0.2× 76 0.7× 37 471
Thilo Zander Switzerland 10 143 0.6× 95 0.5× 56 0.3× 112 0.6× 61 0.6× 25 308

Countries citing papers authored by Leylah Drusbosky

Since Specialization
Citations

This map shows the geographic impact of Leylah Drusbosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leylah Drusbosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leylah Drusbosky more than expected).

Fields of papers citing papers by Leylah Drusbosky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leylah Drusbosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leylah Drusbosky. The network helps show where Leylah Drusbosky may publish in the future.

Co-authorship network of co-authors of Leylah Drusbosky

This figure shows the co-authorship network connecting the top 25 collaborators of Leylah Drusbosky. A scholar is included among the top collaborators of Leylah Drusbosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leylah Drusbosky. Leylah Drusbosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gouda, Mohamed A., Filip Jankú, Ying Yuan, et al.. (2025). Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research. 31(20). 4299–4310. 1 indexed citations
3.
Haynes, G. Clark, et al.. (2024). Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer. Clinical Cancer Research. 30(24). 5657–5665. 3 indexed citations
4.
Sun, Ryan, Nicole Zhang, Leylah Drusbosky, et al.. (2024). Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort.. Journal of Clinical Oncology. 42(16_suppl). 3545–3545. 1 indexed citations
5.
Hong, Lingzhi, Sonia Patel, Leylah Drusbosky, et al.. (2024). Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. npj Precision Oncology. 8(1). 217–217. 11 indexed citations
6.
Marin‐Acevedo, Julian A., et al.. (2024). Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Cancers. 16(13). 2366–2366. 3 indexed citations
7.
Loree, Jonathan M., Christine M. Parseghian, Michael J. Overman, et al.. (2024). Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 42(3_suppl). 158–158. 1 indexed citations
8.
Wu, Florence T.H., James T. Topham, Chris J. O’Callaghan, et al.. (2024). Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient. JCO Precision Oncology. 8(8). e2400031–e2400031. 2 indexed citations
9.
10.
Childs, Daniel S., Eugene D. Kwon, Mohamed E. Ahmed, et al.. (2023). Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).. Journal of Clinical Oncology. 41(6_suppl). 239–239.
11.
Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228. 1 indexed citations
12.
Heeke, Simon, Lei Feng, Leylah Drusbosky, et al.. (2023). Abstract 4264: The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors. Cancer Research. 83(7_Supplement). 4264–4264. 1 indexed citations
13.
Jiang, Tingting, et al.. (2022). Variation in liquid biopsy cfDNA yield predicted by somatic mutation and clinical phenotypes across primary cancers.. Journal of Clinical Oncology. 40(16_suppl). e13553–e13553.
14.
15.
Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81. 31 indexed citations
16.
Drusbosky, Leylah, Mehmet Asım Bilen, Georges Azzi, et al.. (2021). Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. Journal of Clinical Oncology. 39(15_suppl). 3040–3040. 13 indexed citations
17.
18.
Drusbosky, Leylah, et al.. (2021). Genomic landscape differences in patients with advanced non-small cell lung cancer by sex and age.. Journal of Clinical Oncology. 39(15_suppl). 9108–9108. 1 indexed citations
19.
Drusbosky, Leylah, Kimberly E. Hawkins, Glenda G. Anderson, et al.. (2018). iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).. Journal of Clinical Oncology. 36(15_suppl). 7024–7024.
20.
Meacham, Amy, Elizabeth Wise, Leylah Drusbosky, et al.. (2016). Chemosensitizing AML cells by targeting bone marrow endothelial cells. Experimental Hematology. 44(5). 363–377.e5. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Srinivas K. Tantravahi Breakdown of academic impact, for papers by Smitha Menon Breakdown of academic impact, for papers by M.C. Cox Breakdown of academic impact, for papers by Jean Lopategui Breakdown of academic impact, for papers by Florian Huemer Breakdown of academic impact, for papers by Marco Bono Breakdown of academic impact, for papers by Stephen J Chanock Breakdown of academic impact, for papers by Honghui Huang Breakdown of academic impact, for papers by Thilo Zander
Rankless by CCL
2026